薬剤溶出性バルーンカテーテルの世界市場予測（～2030年）：製品、薬剤、材料、エンドユーザー、地域別の分析

世界の薬剤溶出性バルーンカテーテルの市場規模は、2023年に6億5,100万米ドルを占め、予測期間中にCAGR10.9％で成長し、2030年には13億4,320万米ドルに達すると予想されています。 薬剤溶出性バルーンカテーテル（DEB）と呼ばれる医療機器は、末梢動脈疾患（PAD）や冠動脈疾患（CAD）の治療にインターベンショナル心臓病学で使用されます。

これらのカテーテルの目的は、再狭窄、すなわち血管形成術治療後の血管の収縮を止めるために、損傷した血管壁に直接薬剤を投与することです。薬剤コーティングやカテーテル技術の開発、患者の転帰と安全性の向上に焦点を当てた継続的な臨床研究により、薬剤溶出性バルーンカテーテルの市場は絶えず変化しています。

米国心臓協会の2021年報告書によると、末梢動脈疾患（PAD）は世界中で2億人以上が罹患しており、高い死亡率と罹患率を伴っています。さらに、心血管疾患に罹患しやすい高齢者人口の増加と医療支出の増加が、市場の成長を後押しすると予測されています。

心血管疾患の有病率

動脈閉塞を制御するためのインターベンション治療を必要とする患者の数は、心血管疾患の頻度と連動して増加しています。このような患者にとって、薬剤溶出性バルーンカテーテルは効率的な治療選択肢となるため、同デバイスを使用した治療件数が増加する可能性があります。さらに、医療コストは、経過観察、入院、治療など、心血管疾患の経済的負担の影響を受けます。そのため、薬剤溶出性バルーンカテーテルは、再狭窄や再手術の減少によって長期的な医療費の節約につながることが実証されれば、市場の成長を促す革新的で成功した治療法の一例として、より広く使用される可能性があります。

病変のタイプによっては臨床的エビデンスが限られている

薬剤溶出性バルーンカテーテルの使用を裏付ける臨床データが限られている場合、医療担当者が特定の病変タイプに対して選択できる有効な治療法が少なくなる可能性があります。このような制限により、特定の動脈病変を有する患者が可能な限り最善の治療を受けられなくなる可能性があります。特に、これらのカテーテルが優れた代替手段となり得ると考えられてはいますが、その使用を支持する確かなデータがない場合にはなおさらです。これらのシステムが状況によっては有益であるとしても、よりエビデンスの確立された治療法が選択される可能性があり、市場成長を促進する患者の治療改善のチャンスを逃すことになります。

臨床エビデンスの拡大

薬剤溶出性バルーンカテーテルは安全で有効であり、長期的に良好な結果をもたらしています。このようなデータはその使用を支持し、医療従事者に使用を促しています。薬剤溶出性バルーンカテーテルの優位性を示す臨床データの増加は、医療費支払者の償還判断に好影響を与える可能性があります。患者の転帰がより良いものであることが証明されれば、償還規則がより優遇され、市場アクセスやデバイスの使用率が向上する可能性があります。

コストと償還の課題

薬剤溶出性バルーンカテーテルへの患者のアクセスは、特に保険適用や償還に関する法律が不利な地域や医療システムでは、支払いの問題によって妨げられる可能性があります。このような制限により、患者は最先端の治療法に平等にアクセスできない可能性があり、保険加入状況や地域によっては予後に影響を及ぼす可能性があります。保険償還が困難であったり、保険適用が見送られたりすると、薬剤溶出性バルーンカテーテル市場の浸透や受容が妨げられる可能性があります。

COVID-19の影響

パンデミックの最盛期には、多くの病院や医療施設がリソースを確保する際にCOVID-19患者を優先しました。その結果、薬剤溶出性バルーン血管形成術のような緊急性のない心臓インターベンションを含む選択的手術は、延期またはキャンセルされなければなりませんでした。その結果、これらの機器の市場で実施された手術の数は減少しました。ワクチン接種率が上昇し、医療システムが流行に適応したため、選択的手術と緊急性のないインターベンションは着実に回復しました。複数の医療機関が再開した結果、心血管治療、特に薬剤を放出するバルーンカテーテルを必要とする治療の需要が増加しました。

予測期間中、冠動脈バルーンカテーテル分野が最大となる見込み

冠動脈バルーンカテーテルは、心筋への血液供給を補うために冠動脈の閉塞を解除したり広げたりするものであるため、この分野は有利な成長が見込まれます。特に、薬剤溶出性バルーンカテーテルは、再狭窄を避けるために、動脈閉塞部位に直接薬剤を供給するカテーテルの一種です。さらに、侵襲性の低い処置の必要性、心血管疾患の有病率の上昇、薬剤溶出性バルーンが従来の血管形成術よりも効果的に再狭窄率を低下させるという事実が市場の成長を後押ししています。

パクリタキセルセグメントは予測期間中に最も高いCAGRが見込まれる

薬剤溶出性バルーン（DEB）カテーテルにおけるパクリタキセルの使用は、その安全性、特に末梢動脈疾患（PAD）患者における長期的な影響や死亡率の上昇との関連性が懸念されるため、多くの注目と調査が集まっています。さらに、薬剤溶出性バルーンカテーテルやその他のパクリタキセルコーティング製品は、これらのデバイスを取り巻く安全性への懸念により、市場力学に変化が見られています。そのため、監視の強化、臨床手順の変更、患者の選択と長期的な安全性モニタリングに関する議論が増加しています。

最大のシェアを占める地域

北米は、複数の大手メーカーが存在すること、技術的に洗練された新しい機器の導入、有利な償還政策などが、北米に見られる市場シェアの主な要因となっているため、予測期間中に最大の市場シェアを占めると予測されています。例えば、米国心臓協会の推計によると、米国では経皮経管冠動脈インターベンションを含む経皮的冠動脈形成術が毎年50万件以上実施されています。

CAGRが最も高い地域：

アジア太平洋は、医療コストの上昇と心血管疾患の蔓延により、予測期間中に最も高いCAGRを示すと予測されています。Biomedcentralによると、中国人のほぼ5人に1人が心血管疾患を患っています。さらに、中国や日本のような国では、可処分所得の増加と高齢化により、この分野の需要が高まると予測されています。発展途上国におけるヘルスツーリズムの成長も、この分野における業界の進歩に寄与しています。

無料カスタマイズサービス：

本レポートをご購読のお客様には、以下の無料カスタマイズオプションのいずれかをご利用いただけます：

• 企業プロファイル
  • 追加市場企業の包括的プロファイリング（3社まで）
  • 主要企業のSWOT分析（3社まで）
• 地域セグメンテーション
  • 顧客の関心に応じた主要国の市場推計・予測・CAGR（注：フィージビリティチェックによる）
• 競合ベンチマーキング
  • 製品ポートフォリオ、地理的プレゼンス、戦略的提携に基づく主要企業のベンチマーキング

目次

第1章 エグゼクティブサマリー

第2章 序文

• 概要
• ステークホルダー
• 調査範囲
• 調査手法
  • データマイニング
  • データ分析
  • データ検証
  • 調査アプローチ
• 調査ソース
  • 1次調査ソース
  • 2次調査ソース
  • 前提条件

第3章 市場動向分析

• 促進要因
• 抑制要因
• 機会
• 脅威
• 製品分析
• エンドユーザー分析
• 新興市場
• 新型コロナウイルス感染症（COVID-19）の影響

第4章 ポーターのファイブフォース分析

• 供給企業の交渉力
• 買い手の交渉力
• 代替品の脅威
• 新規参入業者の脅威
• 競争企業間の敵対関係

第5章 世界の薬剤溶出性バルーンカテーテル市場：製品別

• 冠動脈バルーンカテーテル
• 末梢血管バルーンカテーテル

第6章 世界の薬剤溶出性バルーンカテーテル市場：薬剤別

• シロリムス
• パクリタキセル
• その他の薬剤

第7章 世界の薬剤溶出性バルーンカテーテル市場：材料別

• ナイロン
• ポリウレタン
• その他の材料

第8章 世界の薬剤溶出性バルーンカテーテル市場：エンドユーザー別

• 外来手術センター
• カテーテル検査研究所
• 病院と診療所
• その他のエンドユーザー

第9章 世界の薬剤溶出性バルーンカテーテル市場：地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • イタリア
  • フランス
  • スペイン
  • その他欧州
• アジア太平洋
  • 日本
  • 中国
  • インド
  • オーストラリア
  • ニュージーランド
  • 韓国
  • その他アジア太平洋
• 南米
  • アルゼンチン
  • ブラジル
  • チリ
  • その他南米
• 中東とアフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • カタール
  • 南アフリカ
  • その他中東とアフリカ

第10章 主な発展

• 協定、パートナーシップ、コラボレーション、合弁事業
• 買収と合併
• 新製品の発売
• 事業拡大
• その他の主要戦略

第11章 企業プロファイル

• Aachen Resonance GmbH
• B. Braun Melsungen AG
• Becton, Dickinson and Company
• Biotronik AG
• iVascular S.L.U.
• Lepu Medical Technology（Beijing）Co. Ltd.
• MedAlliance
• Medtronic plc
• Biosensors International
• Eurocor GmbH
• Zhejiang Barty Medical Technology Co.Ltd
• Cook Group Incorporated
• Terumo Corporation
• SurModics Inc
• Koninklijke Philips NV
• Jotech GmbH
• MicroPort Scientific Corporation
• Cordis Corporation
• Cardionovum GmbH
• Abbott Laboratories

List of Tables

• Table 1 Global Drug-eluting Balloon Catheters Market Outlook, By Region (2021-2030) ($MN)
• Table 2 Global Drug-eluting Balloon Catheters Market Outlook, By Product (2021-2030) ($MN)
• Table 3 Global Drug-eluting Balloon Catheters Market Outlook, By Coronary Artery Balloon Catheters (2021-2030) ($MN)
• Table 4 Global Drug-eluting Balloon Catheters Market Outlook, By Peripheral Vascular Balloon Catheters (2021-2030) ($MN)
• Table 5 Global Drug-eluting Balloon Catheters Market Outlook, By Drug (2021-2030) ($MN)
• Table 6 Global Drug-eluting Balloon Catheters Market Outlook, By Sirolimus (2021-2030) ($MN)
• Table 7 Global Drug-eluting Balloon Catheters Market Outlook, By Paclitaxel (2021-2030) ($MN)
• Table 8 Global Drug-eluting Balloon Catheters Market Outlook, By Other Drugs (2021-2030) ($MN)
• Table 9 Global Drug-eluting Balloon Catheters Market Outlook, By Material (2021-2030) ($MN)
• Table 10 Global Drug-eluting Balloon Catheters Market Outlook, By Nylon (2021-2030) ($MN)
• Table 11 Global Drug-eluting Balloon Catheters Market Outlook, By Polyurethane (2021-2030) ($MN)
• Table 12 Global Drug-eluting Balloon Catheters Market Outlook, By Other Materials (2021-2030) ($MN)
• Table 13 Global Drug-eluting Balloon Catheters Market Outlook, By End User (2021-2030) ($MN)
• Table 14 Global Drug-eluting Balloon Catheters Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
• Table 15 Global Drug-eluting Balloon Catheters Market Outlook, By Catheterization Laboratories (2021-2030) ($MN)
• Table 16 Global Drug-eluting Balloon Catheters Market Outlook, By Hospitals & clinics (2021-2030) ($MN)
• Table 17 Global Drug-eluting Balloon Catheters Market Outlook, By Other End Users (2021-2030) ($MN)
• Table 18 North America Drug-eluting Balloon Catheters Market Outlook, By Country (2021-2030) ($MN)
• Table 19 North America Drug-eluting Balloon Catheters Market Outlook, By Product (2021-2030) ($MN)
• Table 20 North America Drug-eluting Balloon Catheters Market Outlook, By Coronary Artery Balloon Catheters (2021-2030) ($MN)
• Table 21 North America Drug-eluting Balloon Catheters Market Outlook, By Peripheral Vascular Balloon Catheters (2021-2030) ($MN)
• Table 22 North America Drug-eluting Balloon Catheters Market Outlook, By Drug (2021-2030) ($MN)
• Table 23 North America Drug-eluting Balloon Catheters Market Outlook, By Sirolimus (2021-2030) ($MN)
• Table 24 North America Drug-eluting Balloon Catheters Market Outlook, By Paclitaxel (2021-2030) ($MN)
• Table 25 North America Drug-eluting Balloon Catheters Market Outlook, By Other Drugs (2021-2030) ($MN)
• Table 26 North America Drug-eluting Balloon Catheters Market Outlook, By Material (2021-2030) ($MN)
• Table 27 North America Drug-eluting Balloon Catheters Market Outlook, By Nylon (2021-2030) ($MN)
• Table 28 North America Drug-eluting Balloon Catheters Market Outlook, By Polyurethane (2021-2030) ($MN)
• Table 29 North America Drug-eluting Balloon Catheters Market Outlook, By Other Materials (2021-2030) ($MN)
• Table 30 North America Drug-eluting Balloon Catheters Market Outlook, By End User (2021-2030) ($MN)
• Table 31 North America Drug-eluting Balloon Catheters Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
• Table 32 North America Drug-eluting Balloon Catheters Market Outlook, By Catheterization Laboratories (2021-2030) ($MN)
• Table 33 North America Drug-eluting Balloon Catheters Market Outlook, By Hospitals & clinics (2021-2030) ($MN)
• Table 34 North America Drug-eluting Balloon Catheters Market Outlook, By Other End Users (2021-2030) ($MN)
• Table 35 Europe Drug-eluting Balloon Catheters Market Outlook, By Country (2021-2030) ($MN)
• Table 36 Europe Drug-eluting Balloon Catheters Market Outlook, By Product (2021-2030) ($MN)
• Table 37 Europe Drug-eluting Balloon Catheters Market Outlook, By Coronary Artery Balloon Catheters (2021-2030) ($MN)
• Table 38 Europe Drug-eluting Balloon Catheters Market Outlook, By Peripheral Vascular Balloon Catheters (2021-2030) ($MN)
• Table 39 Europe Drug-eluting Balloon Catheters Market Outlook, By Drug (2021-2030) ($MN)
• Table 40 Europe Drug-eluting Balloon Catheters Market Outlook, By Sirolimus (2021-2030) ($MN)
• Table 41 Europe Drug-eluting Balloon Catheters Market Outlook, By Paclitaxel (2021-2030) ($MN)
• Table 42 Europe Drug-eluting Balloon Catheters Market Outlook, By Other Drugs (2021-2030) ($MN)
• Table 43 Europe Drug-eluting Balloon Catheters Market Outlook, By Material (2021-2030) ($MN)
• Table 44 Europe Drug-eluting Balloon Catheters Market Outlook, By Nylon (2021-2030) ($MN)
• Table 45 Europe Drug-eluting Balloon Catheters Market Outlook, By Polyurethane (2021-2030) ($MN)
• Table 46 Europe Drug-eluting Balloon Catheters Market Outlook, By Other Materials (2021-2030) ($MN)
• Table 47 Europe Drug-eluting Balloon Catheters Market Outlook, By End User (2021-2030) ($MN)
• Table 48 Europe Drug-eluting Balloon Catheters Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
• Table 49 Europe Drug-eluting Balloon Catheters Market Outlook, By Catheterization Laboratories (2021-2030) ($MN)
• Table 50 Europe Drug-eluting Balloon Catheters Market Outlook, By Hospitals & clinics (2021-2030) ($MN)
• Table 51 Europe Drug-eluting Balloon Catheters Market Outlook, By Other End Users (2021-2030) ($MN)
• Table 52 Asia Pacific Drug-eluting Balloon Catheters Market Outlook, By Country (2021-2030) ($MN)
• Table 53 Asia Pacific Drug-eluting Balloon Catheters Market Outlook, By Product (2021-2030) ($MN)
• Table 54 Asia Pacific Drug-eluting Balloon Catheters Market Outlook, By Coronary Artery Balloon Catheters (2021-2030) ($MN)
• Table 55 Asia Pacific Drug-eluting Balloon Catheters Market Outlook, By Peripheral Vascular Balloon Catheters (2021-2030) ($MN)
• Table 56 Asia Pacific Drug-eluting Balloon Catheters Market Outlook, By Drug (2021-2030) ($MN)
• Table 57 Asia Pacific Drug-eluting Balloon Catheters Market Outlook, By Sirolimus (2021-2030) ($MN)
• Table 58 Asia Pacific Drug-eluting Balloon Catheters Market Outlook, By Paclitaxel (2021-2030) ($MN)
• Table 59 Asia Pacific Drug-eluting Balloon Catheters Market Outlook, By Other Drugs (2021-2030) ($MN)
• Table 60 Asia Pacific Drug-eluting Balloon Catheters Market Outlook, By Material (2021-2030) ($MN)
• Table 61 Asia Pacific Drug-eluting Balloon Catheters Market Outlook, By Nylon (2021-2030) ($MN)
• Table 62 Asia Pacific Drug-eluting Balloon Catheters Market Outlook, By Polyurethane (2021-2030) ($MN)
• Table 63 Asia Pacific Drug-eluting Balloon Catheters Market Outlook, By Other Materials (2021-2030) ($MN)
• Table 64 Asia Pacific Drug-eluting Balloon Catheters Market Outlook, By End User (2021-2030) ($MN)
• Table 65 Asia Pacific Drug-eluting Balloon Catheters Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
• Table 66 Asia Pacific Drug-eluting Balloon Catheters Market Outlook, By Catheterization Laboratories (2021-2030) ($MN)
• Table 67 Asia Pacific Drug-eluting Balloon Catheters Market Outlook, By Hospitals & clinics (2021-2030) ($MN)
• Table 68 Asia Pacific Drug-eluting Balloon Catheters Market Outlook, By Other End Users (2021-2030) ($MN)
• Table 69 South America Drug-eluting Balloon Catheters Market Outlook, By Country (2021-2030) ($MN)
• Table 70 South America Drug-eluting Balloon Catheters Market Outlook, By Product (2021-2030) ($MN)
• Table 71 South America Drug-eluting Balloon Catheters Market Outlook, By Coronary Artery Balloon Catheters (2021-2030) ($MN)
• Table 72 South America Drug-eluting Balloon Catheters Market Outlook, By Peripheral Vascular Balloon Catheters (2021-2030) ($MN)
• Table 73 South America Drug-eluting Balloon Catheters Market Outlook, By Drug (2021-2030) ($MN)
• Table 74 South America Drug-eluting Balloon Catheters Market Outlook, By Sirolimus (2021-2030) ($MN)
• Table 75 South America Drug-eluting Balloon Catheters Market Outlook, By Paclitaxel (2021-2030) ($MN)
• Table 76 South America Drug-eluting Balloon Catheters Market Outlook, By Other Drugs (2021-2030) ($MN)
• Table 77 South America Drug-eluting Balloon Catheters Market Outlook, By Material (2021-2030) ($MN)
• Table 78 South America Drug-eluting Balloon Catheters Market Outlook, By Nylon (2021-2030) ($MN)
• Table 79 South America Drug-eluting Balloon Catheters Market Outlook, By Polyurethane (2021-2030) ($MN)
• Table 80 South America Drug-eluting Balloon Catheters Market Outlook, By Other Materials (2021-2030) ($MN)
• Table 81 South America Drug-eluting Balloon Catheters Market Outlook, By End User (2021-2030) ($MN)
• Table 82 South America Drug-eluting Balloon Catheters Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
• Table 83 South America Drug-eluting Balloon Catheters Market Outlook, By Catheterization Laboratories (2021-2030) ($MN)
• Table 84 South America Drug-eluting Balloon Catheters Market Outlook, By Hospitals & clinics (2021-2030) ($MN)
• Table 85 South America Drug-eluting Balloon Catheters Market Outlook, By Other End Users (2021-2030) ($MN)
• Table 86 Middle East & Africa Drug-eluting Balloon Catheters Market Outlook, By Country (2021-2030) ($MN)
• Table 87 Middle East & Africa Drug-eluting Balloon Catheters Market Outlook, By Product (2021-2030) ($MN)
• Table 88 Middle East & Africa Drug-eluting Balloon Catheters Market Outlook, By Coronary Artery Balloon Catheters (2021-2030) ($MN)
• Table 89 Middle East & Africa Drug-eluting Balloon Catheters Market Outlook, By Peripheral Vascular Balloon Catheters (2021-2030) ($MN)
• Table 90 Middle East & Africa Drug-eluting Balloon Catheters Market Outlook, By Drug (2021-2030) ($MN)
• Table 91 Middle East & Africa Drug-eluting Balloon Catheters Market Outlook, By Sirolimus (2021-2030) ($MN)
• Table 92 Middle East & Africa Drug-eluting Balloon Catheters Market Outlook, By Paclitaxel (2021-2030) ($MN)
• Table 93 Middle East & Africa Drug-eluting Balloon Catheters Market Outlook, By Other Drugs (2021-2030) ($MN)
• Table 94 Middle East & Africa Drug-eluting Balloon Catheters Market Outlook, By Material (2021-2030) ($MN)
• Table 95 Middle East & Africa Drug-eluting Balloon Catheters Market Outlook, By Nylon (2021-2030) ($MN)
• Table 96 Middle East & Africa Drug-eluting Balloon Catheters Market Outlook, By Polyurethane (2021-2030) ($MN)
• Table 97 Middle East & Africa Drug-eluting Balloon Catheters Market Outlook, By Other Materials (2021-2030) ($MN)
• Table 98 Middle East & Africa Drug-eluting Balloon Catheters Market Outlook, By End User (2021-2030) ($MN)
• Table 99 Middle East & Africa Drug-eluting Balloon Catheters Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
• Table 100 Middle East & Africa Drug-eluting Balloon Catheters Market Outlook, By Catheterization Laboratories (2021-2030) ($MN)
• Table 101 Middle East & Africa Drug-eluting Balloon Catheters Market Outlook, By Hospitals & clinics (2021-2030) ($MN)
• Table 102 Middle East & Africa Drug-eluting Balloon Catheters Market Outlook, By Other End Users (2021-2030) ($MN)

According to Stratistics MRC, the Global Drug-eluting Balloon Catheters Market is accounted for $651.0 million in 2023 and is expected to reach $1343.2 million by 2030 growing at a CAGR of 10.9% during the forecast period. Medical devices called drug-eluting balloon catheters (DEBs) are used in interventional cardiology to treat peripheral arterial disease (PAD) and coronary artery disease (CAD). The purpose of these catheters is to administer medication straight to the damaged blood vessel walls in order to stop restenosis, or the constriction of blood vessels after angioplasty treatments. With developments in drug coatings, catheter technology, and continuing clinical research focused on improving patient outcomes and safety, the market for drug-eluting balloon catheters is continually changing.

According to the American Heart Association 2021 report, peripheral artery disease (PAD) affects more than 200 million people worldwide and is associated with high mortality and morbidity. Moreover, the increasing geriatric population, which is prone to cardiovascular diseases and growing healthcare spending are projected to bolster market growth

Market Dynamics:

Driver:

Prevalence of cardiovascular diseases

The number of individuals in need of interventional therapies to control arterial blockages grows in tandem with the frequency of cardiovascular disorders. For these patients, drug-eluting balloon catheters provide an efficient therapeutic alternative that may result in an increase in the number of procedures using these devices. Additionally, healthcare cost is influenced by the financial burden of cardiovascular illnesses, which includes follow-up care, hospital stays, and therapies. Thus drug-eluting balloon catheters are one example of an innovative and successful treatment that may be more widely used if it can be demonstrated to save long-term healthcare expenditures by reducing restenosis and recurring procedures which encourage the growth of the market.

Restraint:

Limited clinical evidence in some lesion types

There may be fewer effective treatment choices available to healthcare practitioners for particular lesion types if there is limited clinical data supporting the use of drug-eluting balloon catheters. This restriction may result in patients with certain arterial lesions not receiving the best care possible, especially if these are thought to be a potentially good alternative but have no solid data to support their use. Even while these systems could be beneficial in some circumstances, they might choose more well-established therapies with more evidence, missing out on chances to improve patient care thereby propel the growth of the market.

Opportunity:

Expanding clinical evidence

Drug-eluting balloon catheters are safe, effective, and have good long-term results; this data supports their use and encourages healthcare practitioners to use them. Increased clinical data demonstrating the advantages of drug-eluting balloon catheters can have a favourable impact on healthcare payers' judgments about reimbursement. More proof of better patient outcomes might support reimbursement rules that are more favourable, increasing market access and device usage.

Threat:

Cost considerations and reimbursement challenges

Patients' access to drug-eluting balloon catheters may be hampered by payment issues, especially in areas or healthcare systems with unfavourable coverage or reimbursement laws. Due to this restriction, patients may not have equal access to cutting-edge therapies, which might have an effect on their prognosis depending on their insurance status or region. Difficulties with reimbursement or hold-ups in receiving positive coverage decisions might hinder drug-eluting balloon catheters market penetration and acceptance.

Covid-19 Impact

Many hospitals and healthcare facilities gave priority to COVID-19 patients when it came to resources during the pandemic's height. Elective operations, including non-urgent cardiac interventions like drug-eluting balloon angioplasty, had to be postponed or cancelled as a result. As a result, the number of procedures performed on the market for these devices decreased. Elective operations and non-urgent interventions showed a steady recovery as vaccination rates rose and healthcare systems adjusted to the epidemic. As a result of several healthcare institutions starting up again, there was an increase in demand for cardiovascular treatments, especially those requiring balloon catheters that release medication.

The coronary artery balloon catheters segment is expected to be the largest during the forecast period

The coronary artery balloon catheters segment is estimated to have a lucrative growth, as these gadgets are intended to unblock or widen coronary arteries in order to replenish blood supply to the heart muscle. In particular, drug-eluting balloon catheters are a kind of catheter that, in order to avoid restenosis, provide medication right to the location of an arterial blockage. Moreover these are becoming more and more popular; as these devices are driven by factors like the need for less invasive procedures, the prevalence of cardiovascular diseases rising, and the fact that drug-eluting balloons reduce restenosis rates more effectively than traditional angioplasty which drives the growth of the market.

The paclitaxel segment is expected to have the highest CAGR during the forecast period

The paclitaxel segment is anticipated to witness the highest CAGR growth during the forecast period, because its usage in drug-eluting balloon (DEB) catheters has drawn a lot of attention and investigation because of worries about its safety, especially in light of possible long-term consequences and a link to higher death rates in patients with peripheral artery disease (PAD). Furthermore, drug-eluting balloon catheters and other paclitaxel-coated goods have seen changes in their market dynamics due to safety concerns surrounding these devices. Thus increased scrutiny, modifications to clinical procedures and conversations about patient selection and long-term safety monitoring have resulted from it.

Region with largest share:

North America is projected to hold the largest market share during the forecast period owing to the availability of several large manufacturers, the introduction of new, technologically sophisticated equipment, and advantageous reimbursement policies are all key contributors to the market share that is seen in North America. For instance, according to estimates from the American Heart Association, more than 500,000 percutaneous coronary procedures including percutaneous transluminal coronary interventions are performed in the United States each year.

Region with highest CAGR:

Asia Pacific is projected to have the highest CAGR over the forecast period, owing to both the rise in healthcare costs and the prevalence of cardiovascular diseases. According to Biomedcentral, almost one in five Chinese people suffer from cardiovascular disease. Furthermore, it is projected that growing disposable income and an older population in nations like China and Japan would fuel demand in the area. The growth of health tourism in developing nations is also contributing to the industry's progress in this sector.

Key players in the market

Some of the key players profiled in the Drug-eluting Balloon Catheters Market include Aachen Resonance GmbH, B. Braun Melsungen AG, Becton, Dickinson and Company, Biotronik AG, iVascular S.L.U., Lepu Medical Technology (Beijing) Co. Ltd., MedAlliance, Medtronic plc, Biosensors International, Eurocor GmbH, Zhejiang Barty Medical Technology Co.Ltd, Cook Group Incorporated, Terumo Corporation, SurModics Inc, Koninklijke Philips NV, Jotech GmbH, MicroPort Scientific Corporation, Cordis Corporation, Cardionovum GmbH and Abbott Laboratories

Key Developments:

In November 2023, BD launched a new, advanced ultrasound system designed to help improve clinician efficiency when placing peripherally inserted central catheters (PICCs), central venous catheters, IV lines and other vascular access devices.

In October 2023, Philips OneBlade Partners with College Rivals for an Epic Gaming Journey Enabling Gen Z to 'Move Fearlessly' this is the third strategic partnership in a year that aims to strengthen the brand's commitment to reaching the GenZ audience.

In August 2023, Philips expands local manufacturing of Personal Health products in India to serve local demand, in addition to the beauty and grooming products already being made at the site.

Products Covered:

• Coronary Artery Balloon Catheters
• Peripheral Vascular Balloon Catheters

Drugs Covered:

• Sirolimus
• Paclitaxel
• Other Drugs

Materials Covered:

• Nylon
• Polyurethane
• Other Materials

End Users Covered:

• Ambulatory Surgical Centers
• Catheterization Laboratories
• Hospitals & clinics
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Product Analysis
• 3.7 End User Analysis
• 3.8 Emerging Markets
• 3.9 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Drug-eluting Balloon Catheters Market, By Product

• 5.1 Introduction
• 5.2 Coronary Artery Balloon Catheters
• 5.3 Peripheral Vascular Balloon Catheters

6 Global Drug-eluting Balloon Catheters Market, By Drug

• 6.1 Introduction
• 6.2 Sirolimus
• 6.3 Paclitaxel
• 6.4 Other Drugs

7 Global Drug-eluting Balloon Catheters Market, By Material

• 7.1 Introduction
• 7.2 Nylon
• 7.3 Polyurethane
• 7.4 Other Materials

8 Global Drug-eluting Balloon Catheters Market, By End User

• 8.1 Introduction
• 8.2 Ambulatory Surgical Centers
• 8.3 Catheterization Laboratories
• 8.4 Hospitals & clinics
• 8.5 Other End Users

9 Global Drug-eluting Balloon Catheters Market, By Geography

• 9.1 Introduction
• 9.2 North America
  • 9.2.1 US
  • 9.2.2 Canada
  • 9.2.3 Mexico
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 Italy
  • 9.3.4 France
  • 9.3.5 Spain
  • 9.3.6 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 New Zealand
  • 9.4.6 South Korea
  • 9.4.7 Rest of Asia Pacific
• 9.5 South America
  • 9.5.1 Argentina
  • 9.5.2 Brazil
  • 9.5.3 Chile
  • 9.5.4 Rest of South America
• 9.6 Middle East & Africa
  • 9.6.1 Saudi Arabia
  • 9.6.2 UAE
  • 9.6.3 Qatar
  • 9.6.4 South Africa
  • 9.6.5 Rest of Middle East & Africa

10 Key Developments

• 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 10.2 Acquisitions & Mergers
• 10.3 New Product Launch
• 10.4 Expansions
• 10.5 Other Key Strategies

11 Company Profiling

• 11.1 Aachen Resonance GmbH
• 11.2 B. Braun Melsungen AG
• 11.3 Becton, Dickinson and Company
• 11.4 Biotronik AG
• 11.5 iVascular S.L.U.
• 11.6 Lepu Medical Technology(Beijing) Co. Ltd.
• 11.7 MedAlliance
• 11.8 Medtronic plc
• 11.9 Biosensors International
• 11.10 Eurocor GmbH
• 11.11 Zhejiang Barty Medical Technology Co.Ltd
• 11.12 Cook Group Incorporated
• 11.13 Terumo Corporation
• 11.14 SurModics Inc
• 11.15 Koninklijke Philips NV
• 11.16 Jotech GmbH
• 11.17 MicroPort Scientific Corporation
• 11.18 Cordis Corporation
• 11.19 Cardionovum GmbH
• 11.20 Abbott Laboratories